Phase II clinical trials in oncology: Strengths and limitations of two-stage designs

James Schlesselman, Isildinha Reis

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

Two-stage designs are used widely in Phase II oncology clinical trials to reduce the number of patients placed on ineffective experimental therapies. They provide clear-cut rules for stopping early in the event that treatment is not succeeding as hoped and are relatively simple to implement. Such designs, however, can lead to situations in which patient accrual is continued in the face of a clearly inferior treatment. In situations where patients' response can be determined for many or most subjects before additional patients are enrolled, analyses using Bayesian methodology can lead to earlier termination of studies of ineffective treatments and better align the statistical assessment of treatment effect with the therapeutic objectives of study. These points are discussed in context of the role of Phase II clinical trials in the development of new treatments for cancer.

Original languageEnglish (US)
Pages (from-to)404-412
Number of pages9
JournalCancer Investigation
Volume24
Issue number4
DOIs
StatePublished - Jun 1 2006

Keywords

  • Bayesian methods
  • Clinical trials
  • Phase II studies
  • Two-stage designs

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Phase II clinical trials in oncology: Strengths and limitations of two-stage designs'. Together they form a unique fingerprint.

  • Cite this